Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Next Previous
X
Search
Trial Profile

A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pacritinib (Primary) ; Sirolimus; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; First in man; Therapeutic Use

    • Most Recent Events

    • 12 Dec 2023 Primary endpoint has been met (STAT Activity: %pSTAT3+CD4+T cells at day +21 at PAC/SIR/TAC (PAC 100mg BID) , according to Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 12 Dec 2023 Results reporting final data presented at the 65th American Society of Hematology Annual Meeting and Exposition
    • 25 Aug 2023 Number of treatment arms have been increased from 1 to 3 by the addition of Experimental: Phase 1, Level 2 and Experimental: Phase 2 arms. Study design is changed from single-group assignment to sequential.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top